Skip to main content

Zilxi FDA Approval History

FDA Approved: Yes (First approved May 28, 2020)
Brand name: Zilxi
Generic name: minocycline
Dosage form: Topical Foam
Previous Name: FMX103
Company: Foamix Pharmaceuticals Ltd.
Treatment for: Rosacea

Last updated by Judith Stewart, BPharm on Jan 28, 2021.

Zilxi (minocycline) is a topical tetracycline formulation indicated for the treatment of inflammatory lesions of rosacea in adults.

Add as a preferred source on Google Google preffered source badge

Development timeline for Zilxi

DateArticle
May 29, 2020Approval FDA Approves Zilxi (minocycline) Topical Foam for the Treatment of Rosacea
Oct 17, 2019Foamix Announces FDA Acceptance of its New Drug Application for FMX103 Minocycline Foam for the Treatment of Moderate-to-Severe Papulopustular Rosacea
Aug  5, 2019Foamix Submits New Drug Application to U.S. FDA for FMX103 for the Treatment of Moderate-to-Severe Papulopustular Rosacea

See also

Zilxi (minocycline) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer